Utilizing fresh tumor microspheroids of lung cancer patients

MPL-5821, an ESM™-p38 MAPK Inhibitor, Enhances Tumor Immune Response and M1 Macrophage Polarization in a 3D Ex-Vivo System Utilizing Fresh Tumor Microspheroids Of Lung Cancer Patients.

Melanie Mediavilla-Varela Ph.D., Melba Marie Page Ph.D., Jenny Kreahling, Ph.D., Martin Perry, David Moffat, Scott Antonia, M.D.,Soner Altiok, M.D., Ph.D. Nilogen Oncosystems, Macrophage Pharma Limited, H. Lee Moffitt Cancer Center. The Society for Immunotherapy of Cancer (SITC). 11/08/2017 to 11/12/17. National Harbor, MD, USA.